IL2RB

Across TCGA pan-cancer cohorts, IL2RB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL2RB data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IL2RB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL2RB expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and COAD are the cancer types where IL2RB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.213	0.710	.002	12	view →
LUAD	OS	Median	All	0.228	0.788	.003	12	view →
COAD	OS	Median	III,IV	0.239	0.791	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.910	0.679	.030	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL2RB–LIHC (OS)

Open the LIHC breakdown →